Palatin Technologies shares are trading higher after the company announced it completed enrollment for its Phase 2 clinical study of Bremelanotide with topline results expected in Q1 of the 2025 calendar year.

+5.00% Pre

Palatin Technologies Inc. Ordinary Shares

PTN

0.00

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Stock Ratings | Potential Upside of 284.62%! Leerink Partners initiated coverage of Ovid Therapeutics (OVID) with an "Outperform" rating and a $5 price target.

The 2X Long QUBT ETF (QUBX) rose by 15.18% with a trading value of $59.25 million.

Is Archer Aviation’s (ACHR) Defense Pivot Redefining Its Dual-Use Technology Narrative?

TJX Companies Affirms Q4 GAAP EPS Guidance from $1.33-1.36 to $1.33-1.36 vs $1.37 Est

UPDATE 1-Amundi's Mortier worried about Fed independence, cautious on megacap stocks

Curium Announces First Commercial Doses of Diagnostic Radiopharmaceutical in Czech Republic and Slovakia for Patients with Prostate Cancer

NANO Nuclear Energy Executes First Full Tests Of Proprietary, Patent Pending ALIP At Up To 350 Degree Celsius Fluid Temperature At Demonstration Facility In Westchester County, New York

Hempalta Announces $2 Million Private Placement, Proposed Share Consolidation, and Expanding Nature-Based Carbon Program